|
19 Companies |
|
9 Products |
|
9 Products |
|
15 Mechanisms of Action |
|
0 Trials |
|
43 News |
|
- |||| emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial termination: Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Nov 21, 2024
P=N/A, N=13, Terminated, Sponsor: University of Alberta
Completed --> Terminated; Protracted gastrointestinal symptoms were experienced by most patients who were subsequently found to be in the treatment arm on LPV/r. This observation resulted in cessation of enrolment and a decision not to continue the RCT
- ||||| Ocaliva (obeticholic acid) / Intercept
Trial termination, Combination therapy: Study of INT 747 in Combination With URSO in Patients With Primay Biliary Cirrhosis (PBC) (clinicaltrials.gov) - Feb 15, 2024
P2, N=165, Terminated, Sponsor: Intercept Pharmaceuticals
This observation resulted in cessation of enrolment and a decision not to continue the RCT Completed --> Terminated; Study stopped by sponsor due to administrative reasons
- | linerixibat (GSK2330672) / GSK
Enrollment change: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (clinicaltrials.gov) - Jul 19, 2017
P2, N=22, Completed, Sponsor: GlaxoSmithKline
Completed --> Terminated; Study stopped by sponsor due to administrative reasons N=10 --> 22
- | bezafibrate / Generic mfg., ursodeoxycholic acid / Generic mfg.
Trial completion, Combination therapy: BEZURSO: Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis (clinicaltrials.gov) - Feb 23, 2017
P3, N=100, Completed, Sponsor: Assistance Publique - H
N=10 --> 22 Active, not recruiting --> Completed
- | aldafermin (NGM282) / NGM Biopharma
Trial completion, Phase classification, Enrollment change, Trial primary completion date: Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Aug 24, 2016
P2b, N=36, Completed, Sponsor: NGM Biopharmaceuticals, Inc
Active, not recruiting --> Completed Recruiting --> Completed | Phase classification: P2 --> P2b | N=45 --> 36 | Trial primary completion date: Jun 2015 --> Feb 2016
- Trial completion: High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Jun 10, 2016
P=N/A, N=36, Completed, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Recruiting --> Completed | Phase classification: P2 --> P2b | N=45 --> 36 | Trial primary completion date: Jun 2015 --> Feb 2016 Active, not recruiting --> Completed
- linerixibat (GSK2330672) / GSK
Trial completion, Enrollment change: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (clinicaltrials.gov) - Feb 5, 2016
P2, N=10, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=40 --> 10
- | emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion, Enrollment change: Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Dec 4, 2015
P=N/A, N=13, Completed, Sponsor: University of Alberta
Active, not recruiting --> Completed | N=40 --> 10 Active, not recruiting --> Completed | N=80 --> 13
- | linerixibat (GSK2330672) / GSK
Enrollment closed, Trial primary completion date: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (clinicaltrials.gov) - Sep 21, 2015
P2, N=40, Active, not recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | N=80 --> 13 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Oct 2015
- Livmarli (maralixibat) / Mirum Pharma, Takeda
Enrollment change, Trial withdrawal: CASCADE: An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Aug 1, 2015
P2, N=0, Withdrawn, Sponsor: Shire
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> Oct 2015 N=60 --> 0 | Not yet recruiting --> Withdrawn
- linerixibat (GSK2330672) / GSK
Phase classification: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (clinicaltrials.gov) - Jul 13, 2015
P2, N=40, Recruiting, Sponsor: GlaxoSmithKline
N=60 --> 0 | Not yet recruiting --> Withdrawn Phase classification: P1 --> P2
- linerixibat (GSK2330672) / GSK
Trial primary completion date: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (clinicaltrials.gov) - Jun 22, 2015
P1, N=40, Recruiting, Sponsor: GlaxoSmithKline
Phase classification: P1 --> P2 Trial primary completion date: Apr 2015 --> Apr 2016
- | bezafibrate / Generic mfg., ursodeoxycholic acid / Generic mfg.
Enrollment closed, Combination therapy: BEZURSO: Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis (clinicaltrials.gov) - Jun 15, 2015
P3, N=100, Active, not recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Apr 2015 --> Apr 2016 Recruiting --> Active, not recruiting
- |||| Livmarli (maralixibat) / Mirum Pharma, Takeda
Trial completion, Combination therapy: Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Apr 10, 2015
P2, N=66, Completed, Sponsor: Lumena Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment closed, Trial primary completion date: High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Mar 26, 2015
P=N/A, N=40, Active, not recruiting, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Jul 2015
- | Trial completion, Trial primary completion date: Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT (clinicaltrials.gov) - Feb 23, 2015
P1, N=22, Completed, Sponsor: University of Aarhus
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2014 --> Jul 2015 Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014
- linerixibat (GSK2330672) / GSK
Trial primary completion date: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (clinicaltrials.gov) - Jan 22, 2015
P1, N=40, Recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014 Trial primary completion date: Dec 2014 --> Apr 2015
- | aldafermin (NGM282) / NGM Biopharma
Trial completion, Combination therapy: Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Jan 2, 2015
P2, N=45, Completed, Sponsor: NGM Biopharmaceuticals, Inc
Trial primary completion date: Dec 2014 --> Apr 2015 Recruiting --> Completed
- ||||| Livmarli (maralixibat) / Mirum Pharma, Takeda
New P2 trial: CASCADE: An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Dec 22, 2014
P2, N=60, Not yet recruiting, Sponsor: Lumena Pharmaceuticals, Inc.
- ||| Livmarli (maralixibat) / Mirum Pharma, Takeda
Enrollment closed, Combination therapy: Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Dec 5, 2014
P2, N=60, Active, not recruiting, Sponsor: Lumena Pharmaceuticals, Inc.
Recruiting --> Completed Recruiting --> Active, not recruiting
- || Livmarli (maralixibat) / Mirum Pharma, Takeda
Trial primary completion date, Combination therapy: Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Oct 15, 2014
P2, N=60, Recruiting, Sponsor: Lumena Pharmaceuticals, Inc.
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2014 --> Feb 2015
- bezafibrate / Generic mfg., ursodeoxycholic acid / Generic mfg.
Trial primary completion date, Combination therapy: BEZURSO: Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis (clinicaltrials.gov) - Oct 2, 2014
P3, N=92, Recruiting, Sponsor: Assistance Publique - H
Trial primary completion date: Sep 2014 --> Feb 2015 Trial primary completion date: Apr 2015 --> Dec 2016
- | aldafermin (NGM282) / NGM Biopharma
New P2 trial: Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - May 8, 2014
P2, N=45, Recruiting, Sponsor: NGM Biopharmaceuticals, Inc
- EB06 / Light Chain Biosci, Edesa Biotech
Trial termination: Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody (clinicaltrials.gov) - Apr 2, 2014
P2, N=0, Terminated, Sponsor: NovImmune SA
Trial primary completion date: Apr 2015 --> Dec 2016 Recruiting --> Terminated
- fenofibrate / Generic mfg., ursodeoxycholic acid / Generic mfg.
Trial withdrawal, Combination therapy: Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis (clinicaltrials.gov) - Mar 30, 2014
P2, N=0, Withdrawn, Sponsor: University of Miami
Recruiting --> Terminated Not yet recruiting --> Withdrawn
- fenofibrate / Generic mfg., ursodeoxycholic acid / Generic mfg.
Enrollment change, Combination therapy: Fenofibrate in Combination With Ursodeoxycholic Acid (UDCA) in Primary Biliary Cirrhosis (clinicaltrials.gov) - Mar 30, 2014
P2, N=0, Withdrawn, Sponsor: University of Miami
Not yet recruiting --> Withdrawn N=40 --> 0
- | aldafermin (NGM282) / NGM Biopharma
Enrollment open, Combination therapy: Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Mar 19, 2014
P2, N=45, Recruiting, Sponsor: NGM Biopharmaceuticals, Inc
N=40 --> 0 Not yet recruiting --> Recruiting
- linerixibat (GSK2330672) / GSK
Enrollment open: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (clinicaltrials.gov) - Mar 19, 2014
P1, N=40, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Trial completion: Initial Study of Rituximab to Treat Primary Biliary Cirrhosis (clinicaltrials.gov) - Mar 3, 2014
P1/2, N=10, Completed, Sponsor: University of California, Davis
Not yet recruiting --> Recruiting Recruiting --> Completed
- | sertraline / Generic mfg.
Trial completion: Treatment of Cholestatic Pruritus With Sertraline (clinicaltrials.gov) - Feb 22, 2014
P2, N=40, Completed, Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting --> Completed Recruiting --> Completed
- | aldafermin (NGM282) / NGM Biopharma
New P2 trial, Combination therapy: Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Jan 1, 2014
P2, N=45, Recruiting, Sponsor: NGM Biopharmaceuticals, Inc
- emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment closed: Highly Active Antiretroviral Therapy for Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Nov 10, 2013
P=N/A, N=80, Active, not recruiting, Sponsor: University of Alberta
Recruiting --> Completed Not yet recruiting --> Active, not recruiting
- pentoxifylline / Generic mfg.
Enrollment change: Pentoxifylline for Primary Biliary Cirrhosis (clinicaltrials.gov) - Oct 15, 2013
P2, N=20, Completed, Sponsor: The Cleveland Clinic
Not yet recruiting --> Active, not recruiting N=25 --> 20
- pentoxifylline / Generic mfg.
Trial completion: Pentoxifylline for Primary Biliary Cirrhosis (clinicaltrials.gov) - Oct 15, 2013
P2, N=20, Completed, Sponsor: The Cleveland Clinic
N=25 --> 20 Active, not recruiting --> Completed
- | Stelara (ustekinumab) / J&J
Enrollment change: A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid (clinicaltrials.gov) - Sep 8, 2013
P2, N=20, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed N=128 --> 20
- | Stelara (ustekinumab) / J&J
Trial completion: A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid (clinicaltrials.gov) - Sep 8, 2013
P2, N=20, Completed, Sponsor: Janssen Research & Development, LLC
N=128 --> 20 Recruiting --> Completed
- |||| Livmarli (maralixibat) / Mirum Pharma, Takeda
Enrollment open, Combination therapy: Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Aug 14, 2013
P2, N=60, Recruiting, Sponsor: Lumena Pharmaceuticals, Inc.
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||| Livmarli (maralixibat) / Mirum Pharma, Takeda
New P2 trial, Combination therapy: Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Jul 18, 2013
P2, N=60, Recruiting, Sponsor: Lumena Pharmaceuticals, Inc.
- | linerixibat (GSK2330672) / GSK
New P1 trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Repeat Doses of GSK2330672 Administration in Subjects With Primary Biliary Cirrhosis (PBC) and Symptoms of Pruritus (clinicaltrials.gov) - Jul 11, 2013
P1, N=40, Recruiting, Sponsor: GlaxoSmithKline
- New P1 trial: Biliary Excretion of Conjugated Bile Acids in Humans Measured by 11C-cholylsarcosine PET/CT (clinicaltrials.gov) - Jun 16, 2013
P1, N=22, Recruiting, Sponsor: University of Aarhus
- || Tudcabil (tauroursodeoxycholic acid) / Bruschettini
New P3 trial: Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary Cirrhosis (clinicaltrials.gov) - May 16, 2013
P3, N=216, Completed, Sponsor: Beijing Friendship Hospital
- Trial completion: Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis (clinicaltrials.gov) - Jan 24, 2013
P3, N=29, Completed, Sponsor: University of Michigan
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | bezafibrate / Generic mfg., ursodeoxycholic acid / Generic mfg.
Enrollment open, Combination therapy: BEZURSO: Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis (clinicaltrials.gov) - Nov 15, 2012
P3, N=92, Recruiting, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- || bezafibrate / Generic mfg., ursodeoxycholic acid / Generic mfg.
New P3 trial, Combination therapy: BEZURSO: Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis (clinicaltrials.gov) - Jul 30, 2012
P3, N=92, Recruiting, Sponsor: Assistance Publique - H
- Clinical: High-protein High-fiber Diet in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - May 20, 2012
P=N/A, N=40, Recruiting, Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
- Campath (alemtuzumab) / Sanofi
Trial withdrawal: Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Apr 8, 2012
P1, N=0, Withdrawn, Sponsor: Richard Burt, MD
Not yet recruiting --> Recruiting Recruiting --> Withdrawn
- Campath (alemtuzumab) / Sanofi
Enrollment change: Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis (clinicaltrials.gov) - Apr 8, 2012
P1, N=0, Withdrawn, Sponsor: Richard Burt, MD
Recruiting --> Withdrawn N=10 --> 0
- | modafinil / Generic mfg.
Trial completion: Modafinil in the Treatment of Fatigue in Patients With Primary Biliary Cirrhosis (PBC) (clinicaltrials.gov) - Jan 16, 2012
P1, N=40, Completed, Sponsor: Mayo Clinic
N=10 --> 0 Active, not recruiting --> Completed
- ||||| ursodeoxycholic acid / Generic mfg.
New P4 trial: Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis (clinicaltrials.gov) - Jan 11, 2012
P4, N=65, Completed, Sponsor: Dr. Falk Pharma GmbH
- EB06 / Light Chain Biosci, Edesa Biotech
New P2 trial: Primary Biliary Cirrhosis: Investigating A New Treatment Option Using NI-0801, an Anti-CXCL10 Monoclonal Antibody (clinicaltrials.gov) - Sep 6, 2011
P2, N=0, Terminated, Sponsor: NovImmune SA